National Asset Management, Inc. Alaunos Therapeutics, Inc. Transaction History

National Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.04 - $322.5 $12,019 - $3.73 Million	11,557 New	11,557 $20,000
Q2 2022 Aug 12, 2022	SELL	$0.41 - $1.24 $12,464 - $37,698	-30,402 Closed	0 $0
Q4 2021 Jan 28, 2022	SELL	$1.09 - $1.89 $180 - $313	-166 Reduced 0.54%	30,402 $33,000
Q2 2021 Aug 10, 2021	BUY	$2.63 - $3.67 $20,293 - $28,317	7,716 Added 33.77%	30,568 $88,000
Q1 2021 May 13, 2021	BUY	$2.82 - $5.6 $64,442 - $127,971	22,852 New	22,852 $83,000
Q4 2017 Feb 15, 2018	SELL	$4.0 - $6.54 $92,396 - $151,067	-23,099 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$4.99 - $6.57 $50,783 - $66,862	10,177 Added 78.76%	23,099 $144,000
Q2 2017 Aug 15, 2017	BUY	N/A	12,922	12,922 $81,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.